There is no requirement that Cytodyn disclose trial results until they are formally disclosed in the documents they submit to the FDA.

We have all been conditioned to the immediate release of preliminary results that could have been walked back in the FDA submissions and was in a couple cases. This will not do the share price any good and harms Cytodyn's credibility.

Well digested, formal figures will boost the stock price better and for longer and now will show that Cytodyn is on a new, surer path to success. I want to trust the new management lineup and see how they perform and where they are taking us.

No doubt, they want to succeed and I want to succeed!